Key Takeaways
- A quarter defined by disruption, not demand: The Mahad incident, safety revalidation shutdowns, and Red Sea logistics compressed both production and revenue recognition, while the contrast media and sweetener verticals softened for unrelated reasons.
- One high-value intermediate drove outsized growth: The cardiovascular API intermediate (under patent till 2031) grew 250% in Q3, anchoring the pharma intermediate segment and validating the CDMO thesis, albeit from a low base.
- Gross margin held at ~57.5% on softer raw material costs, and management sees a sustainable 57–58% for the near term, with a conservative medium-term view of ~55% as backward integration capex stabilizes.
- The recovery narrative is back-end loaded: Multiple commercial validations, capacity additions, and new product ramp-ups are clustered around Q1–Q3 FY25, making the next two to three quarters a critical execution window.
- What to watch next quarter: The pace of insurance claim reversal, any stabilization in contrast media offtake after the planned Q4 softness, and whether the sweetener dumping pressure eases or persists as guided.
The Mahad Incident: Impact, Response & Recovery Timeline
- What happened: An incident in a localized block of Unit 3 at Mahad resulted in loss of life. Production at the impacted site was ordered to stop by the Maharashtra Pollution Control Board. Compensation was paid to families of the deceased, and injured persons were treated and discharged.
- Financial treatment: Compensation in excess of INR 3 crores was taken as a one-time charge to the P&L. Property damage was also taken as a loss, with reversal expected once the insurer admits the claim, likely in Q4 FY24 to Q1 FY25.
- Safety overhaul underway: The company initiated a complete systemic review of safety systems across all units, engaging renowned external consultants for risk assessment. Additional equipment and systems have been installed, and a senior safety resource has been brought in with responsibility for safety across all units.
- Timeline to restart: The suspensioning process for the affected area will take another six weeks. The company has received approval to initiate capex activities in Unit 3. The backward integration block at Mahad is expected to be validated by Q3 FY25, and a multipurpose block by Q1 FY26.
Shiven Arora: "Our foremost concern was the loss of life due to the accident which can never be compensated."
Pharma Intermediate: The Cardiovascular Molecule Bet
- The growth engine: The PI API vertical delivered 250% growth in Q3 and 194% over nine months, driven entirely by the commercialization of a high-value intermediate for an API under patent protection till 2031, targeting the cardiovascular therapeutic category.
- The ramp-up path: Management expects a significant uptick in volumes when new USFDA-approved capacity in Unit 2 at Ambernath comes on stream in Q1 FY25. The investment plan for the new block completes by March–April of this calendar year, with validation in Q1 FY25 and commercial quantities from Q2 FY25.
- Label expansion upside not priced in: Innovator Esperion received label updation in December, which expands the addressable market for the molecule manifold. Management is sticking to original projections and not factoring in any uptick from this event, making it a potential source of upside surprise.
- The 10x–15x ambition: The company stands by its target of scaling PI API revenue from INR 30–34 crores to 10x–15x over two to three years, anchored by this intermediate. With recent regulatory approvals and label expansion, management sees good traction.
- Capacity is fungible and guarded: Management declined to disclose product-wise peak capacity, stating capacities are fungible and expandable based on customer needs. On being asked if Blue Jet supplies 70–80% of demand for this intermediate, the company would only confirm it is a primary and majority supplier.
VK Singh: "We are, however, sticking to the original projections that we had discussed about and not factoring in any of this uptick that could come from the label updation that's happened."
Contrast Media: Near-Term Softness, Structural Tailwinds
- The sequential decline is partly planned: A planned shutdown contributed to the Q3 sequential decline. Additionally, customers are undertaking capacity expansion for API manufacturing at their own geographies, leading to an immediate softening in offtake. This impact is expected to be limited to Q4 FY24.
- New product launches stack up: A validation quantity for a new contrast media product was shipped in Q3, with validation expected this quarter. Commercial volumes are expected to start from Q2–Q3 FY25 upon completion of the regulatory process at the customer's end.
- NCE intermediate milestones: An NCE intermediate in the MRI space touched an important milestone at the customer's end in December. Commercial offtake is expected to increase from Q2 FY25. Separately, the contrast media customer for another NCE intermediate increased uptake in the first nine months for US supplies, and the innovator received European marketing approval in December 2023.
- Recovery timing: With the ramp-up of NCE intermediates, management expects a strong recovery starting Q1 FY25, with Q1 and Q2 seeing good recovery in this space. The R&D pipeline holds four or five new opportunities.
- World leadership position: In select contrast media intermediates, Blue Jet holds a world leadership position and even exports to China when spare capacity exists. Customers are concentrated among three or four global names, some of whom rely on Blue Jet's backward integration capabilities.
Shiven Arora: "Today in some of the select intermediates in contrast media, we have a world leadership position. To an extent, if there is a requirement and spare capacity, we will export to China."
Artificial Sweeteners: A Price War Blue Jet Won't Fight
- The damage: The sweetener business de-grew 35% in Q3 and 33% over nine months, driven by dumping of products by Chinese manufacturers at very low prices. The company has decided not to drop prices to match, choosing not to enter a price war.
- The strategy: Management is not focusing on the spot market at current prices. Instead, it is reserving capacity for long-term CDMO customers and targeting new customers in Europe and the US. The company is also developing other saccharin variants such as calcium saccharin.
- How long this lasts: The dumping trend may persist for another two to three quarters. The company aims to increase contractual revenues by growing wallet share with existing suppliers and adding new customers, aspiring to grow the category through a strong recovery in saccharine and the addition of other sweeteners.
- The next sweetener: The company is developing another established sweetener for a CDMO opportunity with a large FMCG player, brought up by the customer. Process optimization is underway on the bench before initiating capex.
Margins: Current Strength, Future Normalization
- Gross margin tailwinds: Softer raw material prices helped deliver a gross margin of approximately 57.5% for the nine-month period. Operating costs benefited from a focus on non-renewable energy sources (reducing power cost by 1%) and favorable ocean freight for most of the year, which offset marginal increases in salaries and wages.
- Near-term sustainability: Management expects to sustain 57–58% gross margin for at least a couple of quarters, aided by the reduction in a key raw material.
- Medium-term normalization: In the long run, management sees a couple of percent reduction in gross margin, with medium-term levels settling around 55%. This is tied to the stabilization of backward integration capex. The company described this prediction as "fairly conservative" and noted the catch-up could be aggressive.
- Backward integration as margin anchor: The plan to backward integrate dates back to FY21. Current pricing levels of the key raw material APD are similar to FY22 levels. Management asserts the designed plan will beat the existing supplier and provide further stability and predictability in supplies.
Shiven Arora: "I think the prediction right now is fairly conservative. I think we want, firstly, the capex that we are doing for backward integration to stabilize. The catch-up could be aggressive as well."
Capacity Build-Out & Capex: Laying the Pipes for FY25–26
- Capex trajectory: FY24 capex is tracking to approximately INR 160 crores. FY25 is targeted at INR 200–220 crores. The Mahad investment carries a total outlay of around INR 250 crores, split between FY24 and FY25 depending on when the site is ready for investment; the site is yet to be dismantled.
- Unit 2 capacity (Ambernath): Capacity build-up in Unit 2 will be ready for validation in Q1 FY25, aimed at meeting growing requirements in the pharma intermediate CDMO business and contrast media. This is USFDA-approved and will support the cardiovascular intermediate ramp-up.
- Mahad blocks: Block 1 (backward integration) is expected to be validated by Q3 FY25. Block 2 is a multipurpose intermediate block for CDMOs, covering opportunities in contrast media and pharma intermediates for cardiovascular, CNS, and oncology, with validation expected by Q1 FY26.
- Greenfield site: The company is in the process of making an EC application for a greenfield site and will be fast-tracking investment. Traction is expected in FY25, with a facility expected by FY26.
- New chemistry platforms: The company has added pyrophoric chemistry, enzymatic chemistry, and commenced work on starting elements for proteins (amino acids), though this is in a very early phase. Two or three new chemistry platforms have been added to make the pipeline more robust.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Insurance claim reversal | Reversal of property loss hit in P&L once insurer admits claim | Q4 FY24 to Q1 FY25 |
| Contrast media recovery | Strong recovery to begin, driven by NCE intermediate ramp-ups | Q1 FY25 |
| New contrast media product commercial volumes | Start of commercial volumes upon completion of customer regulatory process | Q2–Q3 FY25 |
| Cardiovascular intermediate volume uptick | Significant uptick when new USFDA-approved capacity in Unit 2 comes on stream | Q1 FY25 |
| MRI NCE intermediate commercial offtake | Commercial offtake to increase | Q2 FY25 |
| Generic iodinated intermediate ramp-up | Significant ramp-up (conservative estimate) | Q2–Q3 FY25 |
| Mahad backward integration block validation | Block validated | Q3 FY25 |
| Mahad multipurpose block validation | Block validated | Q1 FY26 |
| Greenfield site facility | Facility expected | FY26 |
| PI API revenue scale-up | From INR 30–34 crores to 10x–15x | Two to three years |
| Gross margin medium-term level | Normalization to around 55% | Medium term (post backward integration capex stabilization) |
| Sweetener dumping pressure | Trend may last another two to three quarters; company will not enter price war | Two to three quarters |
| FY25 capex | Approximately INR 200–220 crores | FY25 |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Total turnover | Dropped by 1% YoY |
| Contrast media revenue | De-grew by 8% YoY; grew 8% in 9M FY24 |
| Artificial sweetener revenue | De-grew by 35% YoY; de-grew 33% in 9M FY24 |
| Pharmaceutical intermediate revenue | Grew by 250% YoY; grew 194% in 9M FY24 |
| Gross margin | 57.5% for 9M FY24; sustainable at 57–58% for a couple of quarters, medium-term around 55% |
| Profit After Tax | Dropped to 19% in Q3; 23% for 9M FY24 including extraordinary item, compared to 21% in previous year |
| Extraordinary item | In excess of ₹3 cr compensation paid to families of casualties, plus property damage loss at Mahad |
| Cash and investments | ₹237 cr as of 31 December |
| Capex incurred (FY24) | ~₹160 cr expected for FY24, with Mahad investments pushed to FY25 |
| Capex guidance (FY25) | ₹200 cr to ₹220 cr targeted for next financial year |
| Ambernath Unit 2 capex | ₹90 cr to ₹100 cr outlay, validation expected in Q1 FY25 |
| Mahad total capex outlay | ~₹250 cr, split between backward integration block and multipurpose CDMO block |
| Solar project investment | Close to ₹30 cr, completed December 2023, integrated with grid by January 2024 |
| Renewable energy share | More than 60% of total power requirement expected from solar |
| Delivery timelines | 60 to 70 days currently, compared to normal 35 to 40 days, due to Red Sea situation |